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To detect the molecular changes of malignancy in histologically normal breast (HNB) tissues, we recently developed a novel 117gene-malignancy-signature. Here we report validation of our leading malignancy-risk-genes, topoisomerase-2-alpha (TOP2A),
minichromosome-maintenance-protein-2 (MCM2) and “budding-uninhibited-by-benzimidazoles-1-homolog-beta” (BUB1B) at
the protein level. Using our 117-gene malignancy-signature, we classified 18 fresh-frozen HNB tissues from 18 adult female breast
cancer patients into HNB-tissues with low-grade (HNB-LGMA; N = 9) and high-grade molecular abnormality (HNB-HGMA;
N = 9). Archival sections of additional HNB tissues from these patients, and invasive ductal carcinoma (IDC) tissues from six
other patients were immunostained for these biomarkers. TOP2A/MCM2 expression was assessed as staining index (%) and
BUB1B expression as H-scores (0–300). Increasing TOP2A, MCM2, and BUB1B protein expression from HNB-LGMA to HNBHGMA tissues to IDCs validated our microarray-based molecular classification of HNB tissues by immunohistochemistry. We also
demonstrated an increasing expression of TOP2A protein on an independent test set of HNB/benign/reductionmammoplasties,
atypical-ductal-hyperplasia with and without synchronous breast cancer, DCIS and IDC tissues using a custom tissue microarray
(TMA). In conclusion, TOP2A, MCM2, and BUB1B proteins are potential molecular biomarkers of malignancy in histologically
normal and benign breast tissues. Larger-scale clinical validation studies are needed to further evaluate the clinical utility of these
molecular biomarkers.

1. Introduction
Despite recent advances in biomarker discovery, no clinically
proven biomarkers of increased breast cancer risk have
been identified and validated in histologically normal breast.
However, there is increasing evidence in the current literature

for the presence of specific genetic abnormalities in histologically normal breast tissue in patients with and without breast
cancer [1–10]. Such genetic abnormalities are often common
to the tumor and their matched histologically normal breast
tissues, suggesting their association with subsequent development of breast cancer in those patients. Whether such

2
molecular abnormalities are the cause or the eﬀect of the
development of breast cancer is largely unknown. Also
the degree of expression and microanatomical distribution
of these molecular abnormalities in histologically normal/
benign breast tissues is still poorly defined.
In order to elucidate the molecular changes of malignancy in HNB tissues, we used the Aﬀymetrix platform to
profile a large prospective series of fresh-frozen HNB tissues
and invasive ductal breast carcinomas (IDCs). Based on the
diﬀerential expression of a number of IDC-specific genes
in HNB tissues, we developed a novel 117-gene malignancy
signature for molecular classification of HNB tissues into
two subsets that we designated as those with high-grade
and low-grade molecular abnormalities. We subsequently
validated our microarray data on HNB tissues using realtime PCR (qPCR) [11] and demonstrated additional utility
of our malignancy signature by cross-validation analyses on
publically available breast data sets.
Many of the genes in our 117-gene signature were “proliferation genes.” Some of these “proliferation genes” (TOP2A,
MCM2, and BUB1B) are also important targets for breast
cancer therapy. Here we report cross-platform validation of
these 3 genes as our leading candidate malignancy genes
at the protein level. We used immunohistochemistry on a
new set of archival sections of HNB tissues from 18 breast
cancer/DCIS/prophylactic mastectomy patients whose breast
tissues (cancer and normal) were used to derive our 117-gene
malignancy signature in the original microarray experiment.
Since the cells lining the terminal duct lobular units (TDLUs)
are thought to be the precursor cells of breast cancer [12], in
this cross-platform (microarray to IHC) validation analysis
we focused primarily on the immunohistochemical expression of TOP2A, MCM2, and BUB1B in the histologically
normal TDLUs, although we believe that these proteins may
also be useful in the molecular stratification of benign breast
disease and premalignant breast lesions such as atypical
ductal hyperplasia (ADH).

2. Materials and Methods
2.1. Patients and Specimens. This study was carried out
under approval by the Institutional Review Board (IRB) at
the University of South Florida, Tampa, FL. It included 24
adult female patients who underwent mastectomy for their
breast cancers at Moﬃtt Cancer Center (MCC), Tampa, FL
between 2002 and 2005. Eighteen of these patients had freshfrozen histologically normal breast (HNB) tissues previously
analyzed using Aﬀymetrix Plus 2.0 Gene chip to develop
a 117 gene signature to be used for molecular classification of histologically normal breast tissues. Based on the
expression levels of 117-genes in our malignancy signature
(Figure 1), these 18 specimens were classified as HNB tissues
with high-grade and low-grade molecular abnormalities
(HNB-HGMA; N =9 and HNB-LGMA; N =9). Mean ages
for patients with HNB-HGMA and HNB-LGMA were 50
and 55 years, respectively. Pertinent clinicopathologic data,
based on information available from MCC and Contributing
Institutions’ Surgical Pathology reports, electronic patient
records, MCC Cancer Registry, and retrospective review of
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all available H&E slides from MCC Pathology Archives and
outside institutions, is summarized in Table 1.
All available formalin fixed, paraﬃn-embedded (FFPE)
sections from the mastectomies of the study patients (N =
18) were reviewed by an experienced breast pathologist
(AN) to select HNB tissue blocks for immunohistochemical validation of 3 of our leading malignancy-risk genes
(TOP2A, BUB1B, and MCM2). The selection of FFPE block
representative of each HNB tissue was based on the presence
of maximum number of histologically normal terminal duct
lobule units (TDLUs) on a single H&E. stained section
among all of the archival sections reviewed from that patient.
Archival tumor sections from 6 other adult female patients
(mean patient age: 69 years) with IDCs (Cases 1–6; Table 1)
were selected as positive tissue controls to validate the
immunohistochemical expression of TOP2A, MCM2, and
BUB1B protein on archival sections of HNB tissues. Table 2
compares ages for the 3 patient groups in this analysis.
2.2. TOP2A, MCM2, and BUB1B Protein Immunohistochemistry. Five-micron thick serial FFPE sections from each
selected IDC (N = 6), HNB-HGMA (N = 9), and HNBLGMA (N = 9) tissue block were stained with H&E,
and for TOP2A, MCM2, and BUB1B protein proteins,
using immunohistochemical (IHC) protocols optimized in
the Tissue Core Laboratory at our institute (AN). The
IHC staining was carried out using a Ventana Discovery
XT automated system (Ventana Medical Systems, Tucson,
AZ, USA) as per manufacturer’s protocol with proprietary
reagents. Briefly, slides were deparaﬃnized on the automated
system with EZ Prep solution (Ventana). Enzymatic retrieval
was used with Protease 1 solution (Ventana).
The mouse monoclonal antibody that reacts with human
TOP2A protein (#MS-1819-SO, Neomarkers) was used at a
1 : 50 concentration in Dako antibody diluent and incubated
for 60 min. The mouse monoclonal antibody that reacts with
human MCM2 protein (#MS1726PO, Neomarkers) was used
at a 1 : 100 concentration in Dako antibody diluent and
incubated for 4 hours. The BUB1B staining required a 4minute treatment with Ventana Protease 1 prior to a 60minute incubation with the BUB1B antibody (diluted 1 : 100,
Abcam, #AB54894). The Ventana Omni Anti-Mouse HRP
Secondary Antibody (prediluted) was used for 16 min. The
detection system used was the Ventana Omni UltraMap kit,
and slides were then counterstained with hematoxylin. Slides
were dehydrated and cover-slipped as per standard tissue
core laboratory protocol.
2.3. Control Tissues Used for Immunohistochemical Optimization and Test Runs. Positive control tissues that were used for
optimization of the above IHC protocols included tonsillar
lymphoid tissue for TOP2A and MCM2 and spleen for
BUB1B protein, per manufacturer’s recommendations. For
negative controls, the respective primary antibodies were
replaced by commercially available nonimmunized normal
serum. Both types of controls showed satisfactory results.
2.4. Scoring of Immunohistochemical Expression of TOP2A and
MCM2 Proteins. The stained slides were evaluated by the
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Figure 1: Molecular markers of malignancy in histologically normal breast tissues. Context and evolution of our prospective experimental
plan.

(a)

(b)

(c)

(d)

Figure 2: Serial archival sections representative of an IDC stained for H&E, TOP2A, MCM2 and BUB1B proteins. (a) Primary invasive
ductal carcinoma (IDC) of the breast, grade 2, featuring focal tubular diﬀerentiation. (b, c, d) Distinct nuclear immunoreactivity for TOP2A
marking the presence of cycling cells in about 15% of the infiltrating tumor cells, and for MCM2 marking the “licensed” population in
about 1/3rd of the infiltrating tumor cells and diﬀuse cytoplasmic immunoreactivity (2+) with focal cell membrane accentuation for BUB1B
protein (Immunoperoxidase staining (IMPOX staining); original magnifications 200x).

breast pathologist on the study with extensive experience in
immunohistochemistry (AN). Immunohistochemical staining for TOP2A and MCM2 was localized to the nuclei of
the tumor cells and the normal breast epithelium, while the
expression of BUB1B protein was localized to the cytoplasm
of the tumor and normal breast epithelial cells. In order
to calculate TOP2A and MCM2 nuclear staining indices

in IDC tissue sections, up to 2000 tumor cells and in the
case of histologically normal breast tissues (HNB-HGMA
and HNB-LGMA) tissue sections up to 500 nonneoplastic
breast epithelial cells were evaluated by absolute counting
of positive (stained) and negative (unstained) cells in each
section. TOP2A and MCM2 indices were recorded as per
cent positive nuclei as previously described [13]. As outlined

6
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(a)

(b)

(c)

(d)

Figure 3: Serial archival sections representative of histologically normal breast tissues with high-grade molecular abnormality stained for
H&E, TOP2A, MCM2 and BUB1B proteins. (a) Portion of a TDLU from a histologically normal breast tissue with high-grade molecular
abnormality (Case 22, specimen 1495). Serial sections showing the same TDLU as in (a) with distinct nuclear immunoreactivity for TOP2A
(b) and MCM2 (c) in the epithelial cell nuclei, and diﬀuse cytoplasmic immunoreactivity (2+) for BUB1B protein (d) in the mammary
epithelial cells. (IMPOX staining; original magnifications 400x).

in the scheme published by Gonzalez et al. [14], these
evaluations were made in the highest expression areas of the
tumor and histologically normal breast tissues (Figures 2(b),
2(c), 3(b), 3(c), 4(b), and 4(c)).
In the IDCs, both TOP2A- and MCM2-positive tumor
cells were often more frequent at the peripheral/advancing
edge of the tumor mass (Figures 2(b) and 2(c)), while in
HNB tissues such cells were more randomly distributed
within the epithelial lining of the mammary acini and ducts
(Figures 3(b), 3(c), 4(b), and 4(c)). Overall, expression of
these markers was observed predominantly in the mammary
epithelial cells. In some areas, nuclear staining was also noted
in an occasional myoepithelial cell in the outer layers of
the benign mammary acini and ducts. Since myoepithelial
expression was not a consistent finding in most benign
mammary lobules, it was not included in the determination
of TOP2A and MCM2 index.
2.5. Scoring Immunohistochemical Expression of BUB1B Protein. Since the intensity of cytoplasmic staining and the
percentage of epithelial cells stained for BUB1B protein
was variable from case to case and from lobule to lobule
within the same case, a comprehensive immunohistochemical scoring method (H-score method) [15] was used for
semiquantitative evaluation of BUB1B protein expression in
the entire tumor and normal breast tissue sections: BUB1B
protein staining intensity in the malignant (IDC) or benign

breast epithelial cells was scored 0 when there was no
cytoplasmic staining, 1+ for weak, 2+ for intermediate, and
3+ for strong cytoplasmic staining. The products of stained
epithelial cells (%) and the respective staining intensity (0,
1+, 2+, 3+) were added to calculate the total BUB1B protein
immunohistochemical staining score (H-score) for each IDC
tissue and for each histologically normal TDLU in the
HNB tissue section evaluated (Figure 5). The total number
of TDLUs evaluated for immunohistochemical expression
of TOP2A, MCM2, and BUB1B proteins in the HNBHGMA and the HNB-LGMA tissue sections ranged from
6 (no other FFPE section with greater # of TDLUs was
found on review of all archival slides on that case) up to
a maximum of 39 TDLUs/section (Figure 5). The average
number of TDLUs evaluated per HNB tissue section was 31
(range 6 to 39 TDLUs per section) per HNB-HGMA tissue
section analyzed and 24 (range of 17–35 TDLUs per section)
per HNB-LGMA tissue section (Table 3). For most precise
interpretation of immunoreactive nuclei, the sections were
assessed using the 20x objective.
2.6. Diﬀerential Expression of TOP2A Protein in Independent
Sets of Benign, Premalignant, and Cancerous Breast Tissues.
Apart from cross-platform validation of 3 of our leading
malignancy genes in archival HNB tissue samples, we further
demonstrated the diﬀerential expression of TOP2A protein
on independent test sets of Histologically normal breast
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Figure 4: Serial archival sections representative of a histologically normal breast tissues with low-grade molecular abnormality stained for
H&E, TOP2A, MCM2 and BUB1B proteins. (a) Portion of a TDLU from a molecularly low-risk, histologically normal breast tissue (Case 8,
specimen 1481). Serial sections showing the same TDLU as in (a) without any expression of TOP2A (b) and MCM2 (c) in the epithelial cell
nuclei. There is a focal cytoplasmic immunoreactivity (1+ to 2+) for BUB1B protein (d) in some of the mammary epithelial cells in this field.
(IMPOX staining; original magnifications 200x).

tissues, including reduction mammoplasty samples, benign
breast tissue from patients with and without synchronous
breast cancer, and a set of DCIS and invasive breast
carcinomas in a custom-designed breast TMA (Figure 10).
2.7. Statistical Analysis. Analysis of variance was used to
test the diﬀerences among the three sample groups (IDC,
HNB-HGMA, and HNB-LGMA tissues) with the Tukey
method to adjust for P value for pairwise comparison. This
approach was used for analyzing the immunohistochemical
expression data both from the FFPE sections and the breast
TMA. Spearman correlation analysis was used to test the
correlation between immunohistochemical expression of
TOP2A, MCM2, and BUB1B proteins in the 3 sample groups.

3. Results
3.1. Patient Characteristics. The 18 histologically normal
breast tissues with low-grade (N = 9) and high-grade
(N = 9) molecular abnormalities were identified based
on the diﬀerential expression of our breast malignancy
genes from a total of 143 frozen normal breast tissue samples collected from mastectomies in patients with invasive
breast carcinoma, DCIS, or prophylactic mastectomies (prior
microarray experiment). We then summarized pertinent
clinicopathologic characteristics of these patients with HNB

tissues with low-grade molecular abnormalities (Cases 7–
15) and those with high-grade molecular abnormality
(Cases 16–24) (Table 1). Four of the nine patients whose
HNB tissues showed low-grade molecular abnormality on
microarray had the final pathologic diagnosis of IDC, 4
had only DCIS, and 1 had mucinous carcinoma. Of nine
patients whose HNB tissues showed high-grade molecular
abnormality on microarray, two patients had the final
pathologic diagnosis of IDC, one tubular carcinoma, one
adenoid cystic carcinoma, one invasive lobular carcinoma,
one papillary intracystic carcinoma, 2 DCIS, and one patient
had no histologic evidence of malignancy in the prophylactic
mastectomy specimen, despite thorough sampling. The
last patient underwent prophylactic bilateral mastectomy
because of strong family history of breast cancer and had
tested positive for the BRCA1 gene.
Mean age for the patient groups with IDCs, HNBHGMA, and HNB-LGMA tissues was 63, 50, and 55 years,
respectively (Table 2). Based on the analysis of variance
(ANOVA), the diﬀerence in the distribution of patient ages at
the time of diagnosis of their breast cancers (and collection
of histologically normal tissues for the current analysis) was
not statistically significant (P = .29). Since most patients
whose normal breast tissues were found to exhibit HGMA
or LGMA on prior microarray analysis [11] were perimenopausal, the diﬀerential expression of TOP2A, MCM2,
and BUB1B proteins (proliferation gene products) in this
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Table 2: Patient age distribution for IDC, molecularly high-risk and low-risk, histologically normal breast tissue groups.
IDC patients

Mean age
Standard deviation
Total no. of cases

63
14.3
6

Patients with histologically normal breast
tissues with low-grade molecular abnormality
on microarray confirmed by IHC
55
15.16
9

Patients with histologically normal breast
tissues with high-grade molecular abnormality
on microarray confirmed by IHC
50
17.48
9

Table 3: Mean TOP2A and MCM2 indices and BUB1B protein expression scores in IDCs and molecularly high-risk and low-risk,
histologically normal breast tissues.
Archival specimen type
IDCs (N = 6)
Histologically normal breast tissues
with high-grade molecular
abnormality (N = 9) on microarray
Histologically normal breast tissues
with low-grade molecular
abnormality (N = 9) on microarray
P value

Average no. of TDLUs
evaluated/specimen
(Range)
Not applicable

Mean TOP2A
index (%) by
IHC
27 (15–35)

Mean MCM2
index (%) by
IHC
47 (30–80)

Mean BUB1B protein
expression score (H-score) by
IHC (Range)
149 (80–200)

31 (6–39)

11 (2–30)

20 (8–35)

68 (33–113)

24 (17–35)

2 (1–3)

4 (1–12)

17 (10–22)

.18

<.005

<.05

<.005

validation study is unlikely to be due to proliferative eﬀect
of estrogen on the normal/benign breast tissues analyzed.
3.2. TOP2A, MCM2, and BUB1B Protein
Immunohistochemistry
3.2.1. Localization of Immunohistochemical Staining. TOP2A
and MCM2 immunostaining was localized to the nuclei of
the tumor cells (Figures 2(b) and 2(c)) and benign mammary
epithelium (Figures 3(b) and 3(c)), while BUB1B protein
immunostaining was cytoplasmic (Figures 2(d) and 3(d)),
as has been demonstrated in a variety of normal human
tissues [16]. In addition to cytoplasmic localization, an
accentuation of BUB1B immunostaining (Figure 2(d)) was
notable in cell membranes in some of the cases. Overall, a
large proportion of tumor cells in the IDCs demonstrated a
distinct nuclear staining for TOP2A (Figure 2(b) and MCM2
proteins (Figure 2(c)) and cytoplasmic staining for BUB1B
protein (Figure 2(d)). However, the expression of these 3
biomarker proteins was found in smaller proportions of the
epithelial cells lining the TDLUs present in the HNB-HGMA
(Figures 3(b), 3(c), and 3(d)) and HNB-LGMA (Figures
4(b), 4(c), 4(d)) tissues analyzed.
3.2.2. TOP2A Protein Expression in IDCs and Histologically
Normal Breast Tissues with High-Grade and Low-Grade
Molecular Abnormality on Microarray. Expression of TOP2A
was nuclear both in the tumor cells (Figure 2(b)) and in the
acinar and ductal epithelial cells present in the histologically
normal breast tissues with high-grade (Figure 3(b)) and lowgrade (Figure 4(b)) molecular abnormality. Mean TOP2A
nuclear staining index values for IDCs and histologically normal breast tissues with high-grade and low-grade molecular
abnormality were 27, 11, and 2, respectively. Compared to

HNB tissues with low-grade molecular abnormality, TOP2A
expression in HNB tissues with high-grade molecular abnormality was significantly higher, both in terms of absolute
(Table 4) and mean (Table 3, Figure 6) TOP2A expression
indices, thus validating our TOP2A gene expression data
from frozen to archival histologically normal breast tissues
at the protein level.
MCM2 protein expression in IDCs and histologically
normal breast tissues with high-grade and low-grade molecular abnormality on microarray Expression of MCM2 was
nuclear both in the IDC cells (Figure 2(c)) and in the acinar
and ductal epithelial cells present in the histologically normal
breast tissues with high-grade (Figure 3(c)) and low-grade
(Figure 4(c)) molecular abnormality. Mean MCM2 staining
indexes for IDCs and histologically normal breast tissues
with high-grade and low-grade molecular abnormality on
microarray were 47, 20, and 4, respectively, showing higher
immunohistochemical expression of MCM2 in the HNB
tissues with high-grade molecular abnormalities compared
to the HNB tissues with low-grade molecular abnormality
(Table 4, Figure 7), thus validating the same trend as was
evident in our gene expression data. While the majority of
cases in HNB tissues with low-grade molecular abnormality
had MCM2 index of 1-2%, 2 of the cases (Case #s 9 and 14)
(Table 4) had higher MCM2 indices (12% and 8%, resp.),
closer to the MCM2 index of some of the HNB tissues with
high-grade molecular abnormality, suggesting that there may
be a degree of heterogeneity in the expression of MCM2
protein in HNB tissues.
3.2.3. BUB1B Protein Expression in IDCs and Histologically
Normal Breast Tissues with High-Grade and Low-Grade
Molecular Abnormality on Microarray. Mean BUB1B protein
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Figure 5: Whisker plot showing BUB1B protein expression scores
for each individual histologically normal breast tissue with highgrade (N = 9) and low-grade molecular abnormality (N =
9) analyzed. The median BUB1B IHC score for each specimen
is represented by horizontal lines and symbol +, while mean
BUB1B IHC score is represented by Δ. Both mean and median
expression scores for the HNB tissues with high-grade molecular
abnormality on microarray (cases 1489–1497) are higher than
those for the molecularly low-risk HNB tissues with low-grade
abnormality on microarray (cases 1480–1488). Overall, there is a
greater variation in the expression scores for the HNB tissues with
high-grade molecular abnormality as compared to those with lowgrade molecular abnormality (SD = 48.4 versus 24.8; P = .003).
The top row reflects the number of TDLUs that were evaluated for
IHC expression of BUB1B protein in the respective stained section,
representing each histologically normal breast tissue specimen.

cytoplasmic staining scores for IDCs and histologically normal breast tissues with high-grade and low-grade molecular
abnormality on microarray were 149, 68, and 17, respectively
(Table 3). As compared to low-risk normal breast tissues,
this pattern of significantly higher immunohistochemical
expression of BUB1B protein in histologically normal breast
tissues with high-grade molecular abnormality as compared
to low-grade molecular abnormality on microarray confirms
the gene expression trends observed on microarray, thus
validating our BUB1B RNA expression data at the protein
level. Figure 5 shows the distribution of expression of BUB1B
protein in the two molecular sets of histologically normal
breast tissues. The histologically normal breast tissues with
high-grade molecular abnormality had greater number
of TDLUs available for evaluation per individual BUB1B
protein-stained section than the HNB tissues with low-grade
molecular abnormality on microarray molecularly low-risk
group (the average number of breast lobules evaluated was
31 versus 24, resp.), but this diﬀerence was not statistically
diﬀerent (P = .18).
3.2.4. Diﬀerential Expression of TOP2A, MCM2, and BUB1B
Proteins in IDCs and Molecularly High-Risk and Low-Risk,
Histologically Normal Breast Tissues. The immunohistochemical expression scores for TOP2A, MCM2, and BUB1B
protein in the HNB-HGMA tissues were in the intermediate
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range between the higher scores (expression) for the IDCs
and the lower scores (expression) for the HNB-LGMA tissues
(Tables 3 and 4). In fact, for all 3 marker proteins, we
observed a trend toward increasing immunohistochemical
expression (TOP2A and MCM2 indices and BUB1B protein
H-scores) from HNB-LGMA to HNB-HGMA tissues to the
IDC tissues analyzed (Figures 6, 7, and 8). Analysis of variance showed that the diﬀerences in the immunohistochemical expression scores for TOP2A, MCM2, and BUB1B protein
for the three types of tissues were statistically significant (P <
.005 for TOP2A and BUB1B protein, and P < .05 for MCM2
for each pairwise comparison using the Tukey method). The
diﬀerences in expression of these markers for individual pairs
(and respective P values) are shown in Figures 6, 7, and 8.
Furthermore, in comparing the HNB tissues with low-grade
and high-grade molecular abnormality on microarray, the
immunohistochemical expression of these 3 marker proteins
was highly correlated (Spearman correlation ranges 0.84–
0.90 with P value < .0001: r = 0.84 for TOP2A versus
BUB1B, r = 0.9 for TOP2A versus MCM2, and r = 0.88 for
BUB1B versus MCM2). Taken together, these results validate
our microarray expression data for TOP2A, MCM2, and
BUB1B at the protein level in archival histologically normal
breast tissues.
3.2.5. Pathologic Characteristics of the Cases on Breast TMA
Stained for TOP2A. In order to further validate the differential expression of TOP2A protein in various benign,
atypical, premalignant, and cancerous breast tissues, we
immunostained a breast TMA for TOP2A, using the same
IHC protocol as outlined above. The various groups of breast
lesions represented on this TMA were as follows.
Benign Lesions (N = 15). In this group seven adult females
had undergone unilateral or bilateral reduction mammoplasty (RM). Others underwent diagnostic breast tissue
sampling. Final pathologic evaluation showed histologically
normal breast tissues with areas of benign breast disease
(BBD) (N = 10), BBD with focal ductal hyperplasia (FDH)
(N = 2), intraductal papilloma (N = 1), BBD with focus of
atypical lobular hyperplasia (ALH) (N = 1), and BBD with
focal fibroadenomatoid hyperplasia (N = 1).
Atypical Ductal Hyperplasia (ADH) without Invasive Breast
Carcinoma (N = 9). All specimens in this group showed
BBD with foci of ADH. In addition, six (66%) cases showed
columnar cell change and four (44%) had atypical lobular
hyperplasia. There was one case with pseudoangiomatous
stromal hyperplasia (PASH) and one case with an intraductal
papilloma.
ADH with Ipsilateral Invasive or In Situ Breast Carcinoma
(N = 8). All of these cases showed ADH. In addition,
three cases showed areas of invasive ductal carcinoma (IDC)
while 5 cases had ductal carcinoma in situ (DCIS), 2 cases
showed focal columnar cell change, and one of them also
had an intraductal papilloma with atypia, a radial scar, and a
fibroadenoma.
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Figure 6: Immunohistochemical expresssion of TOP2A protein in HNB tissues with low-grade and high-grade molecular abnormalities and
in IDCs. There is an obvious trend toward increasing expression from HNB tissues with low-grade molecular abnormality (white bars) to
those with high-grade molecular abnormality (gray bars), and the IDCs (black bars), thus providing evidence for cross-platform validation
of our original expression profiling data for TOP2A at the protein level. (a) Is the specimen-wise distribution of immunohistochemical
expression of TOP2A for the HNB tissues with low-grade and high-grade molecular abnormality and IDC groups. (b) Is the pairwise
comparison of TOP2A immunostaining among the three groups. For each comparison (e.g., IDC versus normal), a mean diﬀerence with a
95% confidence interval (95% CI) is displayed to examine whether the diﬀerence is statistically significant (A 95% CI deviated away from 0
is statistically significant). The adjusted P value for each comparison, based on Tukey method, is shown.

Ductal Carcinoma In Situ (DCIS) (N = 15). Of the fifteen
specimens in this group, 14 (93%) were intermediate to
high-nuclear grade DCIS and one low-nuclear grade DCIS.
Among these two specimens had areas of adenosis, focal
ductal hyperplasia, PASH, and a fibroadenoma in addition.
Invasive Ductal Breast Carcinomas (N = 20). These were
histologically confirmed IDCs, of which 2 cases also had focal
DCIS, intermediate to high nuclear grade. One IDC showed
focal mucinous diﬀerentiation.
3.2.6. Diﬀerential Expression of TOP2A Protein in Benign,
Atypical, and Premalignant, and Cancerous Breast Tissues.
We found a striking trend toward increasing expression of
TOP2A protein in this independent test set of histologically
normal and benign breast tissues, ADH with or without
synchronous invasive breast carcinoma, DCIS and invasive
ductal breast carcinoma tissues, represented on the breast
TMA. These results provide further validation of increasing
expression of TOP2A protein along the histologic continuum
of various breast lesions from benign to premalignant to
invasive breast carcinomas it’s (Figures 9(a), 9(b), 9(c), and
9(d)). For these specimen types, TOP2A protein expression
data are summarized in Figure 10.

4. Discussion
There is increasing evidence to support the hypothesis
that histologically normal breast tissues contain genetic and
epigenetic abnormalities that render them more susceptible
to neoplastic transformation and that they might be detected
through molecular analyses. In patients with sporadic breast
cancer, abnormalities of breast cancer susceptibility genes,
including TP53, BRCA1, and BRCA2, have been identified in
tumor tissue, and also in histologically normal TDLUs adjacent to carcinoma [17]. In a recent study, Larson et al. found
a threefold increase in allelic imbalance (AI) in histologically
normal breast tissue from sporadic breast cancer patients
and BRCA1 gene mutation carriers as compared to women
who underwent reduction mammoplasty [5], suggesting
that these genetic abnormalities may be contributing to the
risk of development of malignancy. More recently, altered
telomeres and unbalanced allelic loci (markers of genetic
instability) were found both in human breast cancers and in
surrounding histologically normal breast tissues [7]. These
findings provide further support to the “cancer field eﬀect”
concept recognizing the presence of genetically aberrant cells
that may represent high risk cell populations within the histologically normal breast tissues. In a more recent study, [10]
elucidated the molecular diﬀerences between histologically
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Table 4: TOP2A, MCM2, and BUB1B protein expression scores in IDCs, molecularly low-risk and molecularly high risk, histologically
normal breast tissues.
Breast tissue
specimen
Case category (based
no.
on gene
expression
profiling)
1
Carcinoma
2

Carcinoma

3
4
5

Carcinoma
Carcinoma
Carcinoma

6

Carcinoma

7

HNB-LGMA 1

8

HNB-LGMA 2

9

HNB-LGMA 3

10

HNB-LGMA 4

11

HNB-LGMA 5

12

HNB-LGMA 6

13

HNB-LGMA 7

14

HNB-LGMA 8

15

HNB-LGMA 9

16

HNB-HGMA 1

17

HNB-HGMA 2

18

HNB-HGMA 3

19

HNB-HGMA 4

20

HNB-HGMA 5

21

HNB-HGMA 6

22

HNB-HGMA 7

Histologic tumor
Final pathologic
type on initial
diagnosis on
biopsy/lumpectomy
mastectomy
IDC

Histopathologic
findings on
Topoisomerase
archival tissue
II-alpha (TOP2A)
sections selected
index (%)
for IHC
validation
Invasive Cancer
25

IDC, DCIS
Invasive papillary
IDC
CA with a focus Invasive Cancer
30
of IDC
IDC
IDC
Invasive cancer
15
IDC
IDC
Invasive Cancer
35
IDC
IDC
Invasive Cancer
25
IDC w/ lobular
IDC, ILC
Invasive cancer
30
features
HNB tissues with low-grade molecular abnormality (HNB-LGMA)
Benign breast
IDC
IDC
2.5
tissue
Benign breast
IDC
IDC
2.5
tissue
Benign breast
IDC
IDC
2.5
tissue
No residual
Mucinous
Benign breast
mucinous
1
carcinoma
tissue
carcinoma
Residual DCIS,
Benign breast
DCIS
1
multifocal
tissue
Benign breast
IDC
No residual IDC
1
tissue
Benign breast
DCIS
Residual DCIS
2
tissue
Benign breast
DCIS
No residual DCIS
3
tissue
Benign breast
DCIS
Residual DCIS
1
tissue
HNB tissues with high-grade molecular abnormality (HNB-HGMA)
No residual
Adenoid cystic
Benign breast
adenoid cystic
8
carcinoma
tissue
carcinoma
Benign breast
DCIS
DCIS, multifocal
12.5
tissue
No residual
Intracystic
Benign breast
intracystic
12.5
carcinoma
tissue
carcinoma
IDC focal
Benign breast
IDC
9
papillary features
tissue
Benign breast
IDC
IDC
2
tissue
Benign breast
IDC
No residual IDC
15
tissue
Benign breast
tissue-patient
No prior biosy
Benign breast
BRCA1+, strong
10
performed
tissue
family history of
BC

MCM2-index
(%)

BUB1B protein
expression score
(H-score)

30

170

30

135

80
60
50

145
80
165

30

200

2

21

6

20

12

22

2

15

1

10

1

18

2

15

8

11

1

17

12

33

20

64

8

35

30

113

12

46

30

46

25

106

12
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Table 4: Continued.

Breast tissue
specimen
Case category (based
no.
on gene
expression
profiling)
23

HNB-HGMA 8

24

HNB-HGMA 9

Histopathologic
findings on
Histologic tumor
Final pathologic
Topoisomerase
archival tissue
type on initial
diagnosis on
II-alpha (TOP2A)
sections selected
biopsy/lumpectomy
mastectomy
index (%)
for IHC
validation
Benign breast
DCIS
No residual DCIS
4
tissue
No residual
Benign breast
IDC, ILC
invasive
30
tissue
carcinoma

normal breast tissue from breast cancer patients and reduction mammoplasty controls and found a number of global
gene expression abnormalities in the HNB tissues [10].
Using specific epigenetic biomarkers, we have previously
mapped a number of DNA methylation changes in histologically normal breast tissues as a potential explanation
as to why histologically normal breast tissues are at risk
for local recurrence after surgical therapy for breast cancer
[6]. We recently developed a 117-gene signature by comparing the gene expression profiles of a large prospective
cohort of frozen invasive ductal breast carcinoma (IDC)
and histologically normal breast tissues (HNB) from breast
cancer patients [11]. This signature was first cross-validated
on HNB tissues using qPCR including external validation
on previously published datasets [11]. We then used our
117-gene malignancy signature to classify eighteen histologically normal breast tissues with high-grade and low-grade
molecular abnormality, based on the level of expression
of our top malignancy genes. The leading candidate genes
in our malignancy-risk signature were proliferation genes,
including TOP2A, MCM2, and BUB1B.
Here we present the results of cross-platform immunohistochemical validation of these candidate malignancy gene
products (TOP2A, MCM2, and BUB1B proteins) on archival
histological normal breast tissue sections from the mastectomies of the two patient groups in the original microarray experiment (those with HNB tissues with high-grade
and low-grade molecular abnormalities). These candidate
biomarkers were selected for validation based on the gene
expression data and the availability of commercially available
antibodies and to further investigate their usefulness as
biomarkers of molecular abnormalities in histologically
normal and benign breast tissues. We further confirmed the
increasing expression of one of our malignancy-risk gene
products in the present analysis on independent test sets
of histologically normal breast tissues including reduction
mammoplasty samples, which mostly represent the specimens with lowest risk of breast malignancy, histologically
normal/benign breast tissues from patients with and without
synchronous breast cancer and a set of DCIS and invasive
breast carcinomas (IDCs) using a custom-designed breast
TMA (Figure 10).
One of our leading malignancy risk genes identified
on microarray analysis of the histologically normal breast
tissues was topoisomerase II alpha (TOP2A). TOP2A is

MCM2-index
(%)

BUB1B protein
expression score
(H-score)

12

43

35

94

a key enzyme in regulating various chromosomal events
during tumor cell replication. It is one of the markers of
cell proliferation in human breast cancer [18]. It is also the
molecular target for topo II-inhibitors, including anthracyclines (doxorubicin, epirubicin, daunorubicin, idarubicin),
epipodophyllotoxins (etoposide, teniposide), actinomycin,
mitoxantrone, and others [19–21]. The TOP2A gene is
located adjacent to the HER-2 oncogene at the chromosome
location 17q12q21 and is either amplified or deleted in
breast cancer, with or without HER-2 amplification. Recent
evidence suggests that amplification or deletion of TOP2A
gene may account for sensitivity or resistance to topo IIinhibitor (anthracycline) therapy in breast cancer [21].
However, little is known about the role of TOP2A in
histologically normal/benign breast tissues.
We identified TOP2A as a part of the malignancyrisk signature on our microarray experiment and, in this
study, validated its expression at protein level as a potential
biomarker of risk of malignancy in histologically normal
breast tissues. In the archival sections from histologically normal breast tissues with high-grade and low-grade
molecular abnormalities, we evaluated a large number of
“morphologically normal TDLUs” and found that the level of
expression of TOP2A protein in HNB tissues with high-grade
molecular abnormality on microarray was intermediate
between the expression levels in the HNB tissues with lowgrade molecular abnormality on microarray and invasive
ductal breast carcinoma tissues analyzed. Furthermore, the
diﬀerences in the TOP2A expression levels between the
two subsets of molecularly abnormal histologically normal
breast tissues and IDCs were statistically significant. Since
amplification of TOP2A gene leads to the overexpression
of the TOP2A protein and better response to anthracycline
therapy [22], while deletion of TOP2A gene leads to
marked reduction in the expression of TOP2A protein and
primary chemoresistance to TOP2 inhibitor drugs [23], our
findings in histologically normal breast tissues, if clinically
validated in larger series of histologically normal and benign
breast tissues, may have potential implications for future
chemopreventive trials in patients with various atypical and
pre-malignant breast lesions.
Since TOP2A amplified tumor cells tend to be sensitive
to topo-II inhibitor therapy while TOP2A deleted tumor cells
tend to be resistant to anthracycline chemotherapy [21], the
overall response of a given breast cancer case will depend on
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Figure 7: Immunohistochemical expression of BUB1B protein in HNB tissues with low-grade and high-grade molecular abnormalities and
in IDCs. There is an obvious trend toward increasing expression from HNB tissues with low-grade molecular abnormality (white bars) to
those with high-grade molecular abnormality (gray bars), and the IDCs (black bars), thus providing evidence for cross-platform validation
of our original expression profiling data for BUB1B at the protein level. (a) Is the specimen-wise distribution of immuno-histochemical
expression of BUB1B for the HNB tissues with low-grade and high-grade molecular abnormality and IDC groups. (b) Is the pairwise
comparison of BUB1B immunostaining among the three groups. The adjusted P value for each comparison, based on Tukey method, is
shown on (b).

the relative proportions of the 2 cell types. Furthermore, in
locally advanced breast cancer, TOP2A levels in the primary
tumor have been associated with greater tumor response
to anthracycline therapy. It is, therefore, conceivable that
in the case of molecularly abnormal histologically normal
breast tissues increased expression of TOP2A may not only
serve as a molecular biomarker of malignancy, but may
also be potentially predictive of chemosensitivity to TOP2A
inhibitors, in order to repress proliferation and subsequent
transformation. These aspects merit further investigation
on larger series of histologically normal and benign breast
tissues.
MCM family of proteins are a novel class of proliferation
markers, of which MCM2 is part of the prereplicative
complex (pre-RC) that is assembled at the site of future
DNA replication during the G1 phase to allow genome
replication in the subsequent S phase. High-MCM2 index
has been shown to correlate with high Ki-67 labeling [24]
and has been shown to be a prognostic marker in a variety
of human malignancies, including cancers of the esophagus,
prostate, stomach and in diﬀuse large B-cell lymphoma
[24–28]. In breast cancers, it appears to be a strong
independent prognostic marker and the degree of MCM2
immunoreactivity has been correlated with high histologic
grade [14, 29, 30]. In normal breast epithelium MCM2 has
been shown to be a more sensitive marker of proliferation

than the widely used proliferation marker, Ki-67 [14, 31],
since it stains both the cycling cells and also the noncycling
cells with proliferative potential [32]. However, not much is
known regarding the association between MCM2 expression
in normal and benign breast tissues.
In our malignancy-gene signature, MCM2 was one of the
leading malignancy-associated genes in a set of histologically
normal breast tissues from peri-menopausal beast cancer
patients. In this study, using the standard immunohistochemical approach, we have observed that the MCM2 index
in HNB tissues with high-grade molecular abnormality was
in the intermediate range between IDCs and HNB tissues
with low-grade molecular abnormality, thus validating the
overexpression of MCM2 protein in the set of HNB tissues
that were showed high-grade molecular abnormality on our
original microarray data analysis.
In this study, we found expression of MCM2 protein
in all of our cases of histologically normal breast tissues.
Considering all of our normal breast samples together, the
observed MCM2 index ranged from 1% to 35%. This wider
variation is a reflection of an inherent case selection bias
in our study, since we selected the 2 subsets of histologically normal breast tissues (with high- and low-grade
molecular abnormality) based on diﬀerential expression of
our malignancy- (proliferation-) associated genes. In a set
of normal breast tissues from reduction mammoplasties,
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Figure 8: Immunohistochemical expresssion of MCM2 protein in HNB tissues with low-grade and high-grade molecular abnormalities and
in IDCs. There is an obvious trend toward increasing expression from HNB tissues with low-grade molecular abnormality (white bars) to
those with high-grade molecular abnormality (gray bars), and the IDCs (black bars), thus providing evidence for cross-platform validation
of our original expression profiling data for MCM2 at the protein level. (a) Is the specimen-wise distribution of immunohistochemical
expression of MCM2 for the HNB tissues with low-grade and high-grade molecular abnormality and IDC groups. (b) Is the pairwise
comparison of MCM2 immunostaining among the three groups. The adjusted P value for each comparison, based on Tukey method, is
shown on (b).

Shetty et al. found a median MCM2 expression of 35%
[31]. This high level of expression is comparable to the
highest levels of MCM2 expression in the HNB tissues with
high-grade molecular abnormality in our study. Although
normal breast tissues in the above study [31] were from
the lowest risk specimens (reduction mammoplasties), a
probable explanation for higher MCM2 indices in their study
was premenopausal status of their patients, since estrogens
are known to be a major promoter of proliferation in normal
breast epithelium [33]. On the contrary, in our study it
is unlikely that the higher MCM2 and other proliferation
biomarkers (TOP2A and BUB1B) in the molecularly abnormal breast tissue samples were due to hormonal (estrogen)
milieu of the patients studied, since both sets of HNB
tissues (with high- and low-grade molecular abnormalities)
in our study were from perimenopausal patients without
any significant statistical diﬀerence in their ages. Therefore,
a higher MCM2 expression in histologically normal breast
tissues in our study is most likely a true molecular biomarker
of malignancy rather than an estrogen-driven phenomenon.
In another recent study of benign breast tissues from
30 patients who underwent lumpectomy for fibrocystic
changes, ductal hyperplasia, and fibroadenomas, the overall
MCM2 labeling index was from 0% to 12% [30]. This
pattern of expression is comparable to the HNB tissues
with low-grade molecularl abnormality in our study. In

our preliminary analysis, we did not find an obvious and
linear relationship between the expression of MCM2 and
the histologically defined risk categories of benign breast
disease. Interestingly, we found higher expression of MCM2
and other proliferation marker proteins in histologically
normal TDLUs as compared to the adjacent hyperplastic
lobular units and incidental areas of epithelial hyperplasia
on the same histologic sections of HNB tissues. This
suggests that the expression of our malignancy-associated
proliferation marker proteins may be independent of the
various histologic risk categories of benign breast disease as
was originally defined on the basis of degree of epithelial
proliferation and cytologic atypia [34–36], and subsequently
endorsed at a Consensus Conference of the College of
American Pathologists [37]. We are intrigued by this finding
and would like to extend this into a systematic analysis of
the expression of these biomarkers and various benign and
preneoplastic histologic correlates of breast cancer risk, as
they have been recognized in the literature over the years
[35, 38–42].
BUB1B protein is a mitotic checkpoint kinase required
for cell mitotic divisions following severe cell damage or
mutation [43, 44]. It has been associated with cell proliferation both in neoplastic and nonneoplastic tissues [16,
45, 46] and also with tumor progression [47, 48]. BUB1B
is also a cellular target of synuclein-gamma (SNCG, also
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Figure 9: Immunohistochemical expression of TOP2A protein. (a) Histologically normal breast tissue from a reduction mammoplasty (RM)
case featuring lack of nuclear expression of TOP2A in the epithelial cells lining a normal TDLU. (b) Histologically normal breast tissue from a
patient with synchronous breast cancer showing positive nuclear staining in 4-5% of the mammary epithelial cells-higher TOP2A expression
than the HNB tissues from a reduction mammoplasty case illustrated in (a). (c-d) A larger proportion of epithelial cells are immunoreactive
for nuclear TOP2A protein in ductal carcinoma in situ (DCIS) and in the invasive ductal carcinoma (IDC) infiltrating the mammary fat.
These cases illustrate an obvious increase in TOP2A protein expression from the lowest risk specimen from a reduction mammoplasty case
(a), to the higher-risk specimens (c) and (d) (IMPOX staining for TOP2A; original magnifications 200x).
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Figure 10: Mean TOP2A index in independent test sets of histologically normal breast (including reduction mammoplasty tissues),
histologically normal and benign breast tissues from patients without and with synchronous cancer, DCIS and invasive breast carcinoma
tissues. There is an obvious trend toward increasing TOP2A expression from benign to malignant breast tissues.
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known as breast cancer specific gene 1), with which it may
interact to inactivate the mitotic checkpoint, and contribute
to resistance of beast cancer cells to microtubule inhibitors.
Recently, a strong association has been found between
BUB1B and other mitotic checkpoint genes and breast
cancer risk [49]. Furthermore, checkpoint genes, including
BUB1B, are expressed at high levels in breast cancer, both at
transcriptional (RNA) and translational (protein) levels [50].
In this study, we have validated overexpression of BUB1B
protein in histologically normal breast tissues that were
found to be molecularly abnormal on microarray, thus
validating our prior microarray and real-time PCR results.
Our study suggests that BUB1B overexpression may be
a new immunohistochemical biomarker of malignancy in
histologically normal breast tissues. It will also be interesting to investigate the role of BUB1B overexpression as
a potential therapeutic target for microtubule inhibitors
and an immunohistochemical biomarker of predictive of
chemosensitivity of atypical and pre-malignant breast lesions
to these antimitotic agents.
Expression of hormone receptors is an established predictor of response of breast cancer to hormonal therapy
in breast cancer, but markers predictive of chemosensitivity of breast cancer are less well defined [51]. In
addition, markers that could predict eﬀective prevention
of human breast cancer in high-risk patient populations
are largely unknown. Among the proliferation-associated
proteins (TOP2A, MCM2, and BUB1B) that we have studied
immunohistochemically on a set of IDCs and validated as
immunohistochemical biomarkers of malignancy in histologically normal breast tissues, TOP2A and BUB1B protein
are also known targets of established chemotherapeutic
approaches in breast cancer: anthracyclines and antimicrotubule therapies, respectively. It will, therefore, also be
interesting to explore how these biomarkers can be utilized
as predictors of breast cancer response to TOP2A and
antimicrotubule inhibitors.

5. Summary
To our knowledge, this is the first IHC-based analysis focusing on the pattern of coexpression of newer proliferationassociated proteins (TOP2A, MCM2, and BUB1B) in histologically normal breast tissues. In continuation of our prior
transcriptional validation using qPCR, in this immunohistochemical validation study, we have demonstrated significantly higher expression of TOP2A, MCM2, and BUB1B
proteins in a set of histologically normal breast tissues
that were found to have high-grade molecular abnormality
on microarray, based on our novel 117-gene malignancy
signature. Taken together, these data further validate our
leading candidate malignancy-risk genes (TOP2A, MCM2,
and BUB1B) at the protein level. In addition, we have
shown incremental expression of TOP2A protein on independent test sets of histologically normal breast tissues
(including reduction mammoplasty samples), histologically
normal/benign breast tissue from patients with and without
synchronous breast cancer, and a set of DCIS and invasive
breast carcinomas using a custom breast TMA. This study
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reveals new information about the coexpression of TOP2A,
MCM2, and BUB1B proteins in histologically normal breast
tissues and provide preliminary evidence to support further
analyses of these proteins on larger series of histologically
normal, benign, pre-malignant, and malignant breast tissues.
Specifically, determination of TOP2A, MCM2, and BUB1B
protein expression status may provide an objective tool
to evaluate of the molecular signature of malignancy in
histologically normal and benign breast tissues.
The immunohistochemical approach used here oﬀered
some distinct technical advantages over other techniques
like qPCR or microarray: (1) combined assessment of the
degree of expression (high versus low), microanatomical
distribution (diﬀuse versus patchy), tissue (epithelial versus stromal), and subcellular (nuclear versus cytoplasmic)
localization of the biomarker proteins in a given sample; (2)
comparative evaluation of the relative expression of these
marker proteins in histologically normal TDLUs and various
incidental benign and pre-malignant breast lesions present
in the same archival breast tissue sections. We do recognize
one of the limitations of our study—the fewer numbers of
histologically normal breast tissue analyzed. However, since
we have successfully validated the expression of TOP2A,
MCM2, and BUB1B proteins in HNB tissues with various
grades of molecular abnormalities, we are in the process of
now expanding our investigation to larger sample size and a
wider range of benign pre-malignant and malignant breast
tissues.

6. Conclusions
The data presented in this technical validation study of a
novel set of molecular biomarkers (TOP2A, MCM2, and
BUB1B proteins) in histologically normal breast tissues
confirms our microarray data at the protein level. We
have also unraveled a preliminary association between the
expression of these marker proteins and diﬀerent stages of
mammary carcinogenesis (histologically normal to benign to
pre-malignant and fully invasive malignant breast tissues).
Additional studies on larger selection of histologically normal, benign, and pre-malignant breast tissues are needed to
fully explore the clinical utility of these biomarkers in the
stratification of histologically normal breast and benign and
premalignant breast lesions into those with various levels of
molecular abnormalities. Such classification may potentially
be predictive of response of various benign, atypical, and premalignant to targeted chemopreventive approaches.
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